KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Return on Sales (2019 - 2025)

Historic Return on Sales for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to 0.57%.

  • Royalty Pharma's Return on Sales rose 100.0% to 0.57% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.56%, marking a year-over-year decrease of 300.0%. This contributed to the annual value of 0.56% for FY2025, which is 300.0% down from last year.
  • Royalty Pharma's Return on Sales amounted to 0.57% in Q4 2025, which was up 100.0% from 0.73% recorded in Q3 2025.
  • Royalty Pharma's Return on Sales' 5-year high stood at 1.45% during Q2 2021, with a 5-year trough of 1.08% in Q4 2022.
  • Over the past 5 years, Royalty Pharma's median Return on Sales value was 0.47% (recorded in 2022), while the average stood at 0.5%.
  • As far as peak fluctuations go, Royalty Pharma's Return on Sales crashed by -11700bps in 2022, and later skyrocketed by 22800bps in 2023.
  • Quarter analysis of 5 years shows Royalty Pharma's Return on Sales stood at 0.09% in 2021, then tumbled by -1257bps to 1.08% in 2022, then surged by 212bps to 1.2% in 2023, then plummeted by -53bps to 0.56% in 2024, then grew by 2bps to 0.57% in 2025.
  • Its Return on Sales stands at 0.57% for Q4 2025, versus 0.73% for Q3 2025 and 0.16% for Q2 2025.